ICAD
Price
$1.75
Change
-$0.02 (-1.13%)
Updated
May 17, 6:59 PM EST
74 days until earnings call
ILMN
Price
$111.07
Change
-$3.39 (-2.96%)
Updated
May 17, 6:59 PM EST
81 days until earnings call
Ad is loading...

ICAD vs ILMN

Header iconICAD vs ILMN Comparison
Open Charts ICAD vs ILMNBanner chart's image
iCAD
Price$1.75
Change-$0.02 (-1.13%)
Volume$188.62K
CapitalizationN/A
Illumina
Price$111.07
Change-$3.39 (-2.96%)
Volume$528.14K
CapitalizationN/A
View a ticker or compare two or three
ICAD vs ILMN Comparison Chart

Loading...

ICADDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ILMNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ICAD vs. ILMN commentary
May 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICAD is a Hold and ILMN is a StrongBuy.

COMPARISON
Comparison
May 19, 2024
Stock price -- (ICAD: $1.75 vs. ILMN: $111.07)
Brand notoriety: ICAD: Not notable vs. ILMN: Notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ICAD: 135% vs. ILMN: 65%
Market capitalization -- ICAD: $42.43M vs. ILMN: $21.09B
ICAD [@Medical Specialties] is valued at $42.43M. ILMN’s [@Medical Specialties] market capitalization is $21.09B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.49B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ICAD’s FA Score shows that 1 FA rating(s) are green whileILMN’s FA Score has 0 green FA rating(s).

  • ICAD’s FA Score: 1 green, 4 red.
  • ILMN’s FA Score: 0 green, 5 red.
According to our system of comparison, ICAD is a better buy in the long-term than ILMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ICAD’s TA Score shows that 4 TA indicator(s) are bullish while ILMN’s TA Score has 4 bullish TA indicator(s).

  • ICAD’s TA Score: 4 bullish, 6 bearish.
  • ILMN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ILMN is a better buy in the short-term than ICAD.

Price Growth

ICAD (@Medical Specialties) experienced а +15.89% price change this week, while ILMN (@Medical Specialties) price change was +0.49% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.34%. For the same industry, the average monthly price growth was +4.51%, and the average quarterly price growth was +16.96%.

Reported Earning Dates

ICAD is expected to report earnings on Aug 01, 2024.

ILMN is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Medical Specialties (+2.34% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for ICAD with price predictions.
OPEN
A.I.dvisor published
a Summary for ILMN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ILMN($21.1B) has a higher market cap than ICAD($42.4M). ICAD YTD gains are higher at: -1.130 vs. ILMN (-20.231). ICAD has higher annual earnings (EBITDA): -12.18M vs. ILMN (-608M). ILMN has more cash in the bank: 1.05B vs. ICAD (19M). ICAD has less debt than ILMN: ICAD (514K) vs ILMN (2.26B). ILMN has higher revenues than ICAD: ILMN (4.5B) vs ICAD (25.4M).
ICADILMNICAD / ILMN
Capitalization42.4M21.1B0%
EBITDA-12.18M-608M2%
Gain YTD-1.130-20.2316%
P/E RatioN/A49.50-
Revenue25.4M4.5B1%
Total Cash19M1.05B2%
Total Debt514K2.26B0%
FUNDAMENTALS RATINGS
ICAD vs ILMN: Fundamental Ratings
ICAD
ILMN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
4163
P/E GROWTH RATING
1..100
10091
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ICAD's Valuation (33) in the Computer Peripherals industry is somewhat better than the same rating for ILMN (84) in the Biotechnology industry. This means that ICAD’s stock grew somewhat faster than ILMN’s over the last 12 months.

ICAD's Profit vs Risk Rating (100) in the Computer Peripherals industry is in the same range as ILMN (100) in the Biotechnology industry. This means that ICAD’s stock grew similarly to ILMN’s over the last 12 months.

ILMN's SMR Rating (95) in the Biotechnology industry is in the same range as ICAD (96) in the Computer Peripherals industry. This means that ILMN’s stock grew similarly to ICAD’s over the last 12 months.

ICAD's Price Growth Rating (41) in the Computer Peripherals industry is in the same range as ILMN (63) in the Biotechnology industry. This means that ICAD’s stock grew similarly to ILMN’s over the last 12 months.

ILMN's P/E Growth Rating (91) in the Biotechnology industry is in the same range as ICAD (100) in the Computer Peripherals industry. This means that ILMN’s stock grew similarly to ICAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ICADILMN
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
72%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
65%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 6 days ago
68%
Declines
ODDS (%)
Bearish Trend 13 days ago
88%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
78%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
80%
View a ticker or compare two or three
Ad is loading...
ICADDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ILMNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMST3.770.31
+8.96%
Amesite
BRY7.210.11
+1.55%
Berry Corp
CHK91.690.58
+0.64%
Chesapeake Energy Corp
MLTX39.75-1.11
-2.72%
MoonLake Immunotherapeutics
ALAR25.37-1.91
-7.00%
Alarum Technologies Ltd

ICAD and

Correlation & Price change

A.I.dvisor tells us that ICAD and HAE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ICAD and HAE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICAD
1D Price
Change %
ICAD100%
-1.13%
HAE - ICAD
32%
Poorly correlated
+0.98%
ILMN - ICAD
29%
Poorly correlated
-2.96%
NARI - ICAD
29%
Poorly correlated
-1.19%
CVRX - ICAD
27%
Poorly correlated
+2.60%
CTKB - ICAD
26%
Poorly correlated
-1.29%
More